Honz Pharmaceutical Co., Ltd. (SHE:300086)
China · Delayed Price · Currency is CNY 6.10
-0.06 (-0.97%)
Jun 11, 2026, 3:04 PM CST
Honz Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -234.03 | -216.21 | 11.53 | -187.58 | 10.99 |
Depreciation & Amortization | 67.84 | 63.14 | 77.43 | 50.25 | 44.66 |
Other Amortization | 9.64 | 13.13 | 12.7 | 9.52 | 12.11 |
Loss (Gain) From Sale of Assets | -0.47 | 0.23 | -0.72 | 2.8 | -0.07 |
Asset Writedown & Restructuring Costs | 84.38 | 62.63 | 12.79 | 34.06 | 0.42 |
Loss (Gain) From Sale of Investments | -1.45 | -16.69 | - | 4.79 | -46.79 |
Provision & Write-off of Bad Debts | - | -4 | 2.48 | 13 | 13.52 |
Other Operating Activities | 5.99 | 32.65 | 22.53 | 19.38 | 24.7 |
Change in Accounts Receivable | 76.19 | 92.7 | 2.71 | 23.02 | -49.6 |
Change in Inventory | 28.26 | 35.58 | -67.6 | 33.72 | 10.57 |
Change in Accounts Payable | 110.47 | 15.85 | -8.17 | 54.77 | -13.38 |
Operating Cash Flow | 121.24 | 71.46 | 70.69 | 29.32 | 11.33 |
Operating Cash Flow Growth | 69.66% | 1.08% | 141.09% | 158.82% | - |
Capital Expenditures | -92.12 | -92.5 | -137.56 | -58.9 | -219.97 |
Sale of Property, Plant & Equipment | 0.08 | 0.36 | 5.52 | 2.74 | 0.14 |
Cash Acquisitions | - | -1.25 | -1.16 | - | - |
Divestitures | - | 9.48 | - | 37.74 | 333.49 |
Investment in Securities | - | - | - | - | -27 |
Other Investing Activities | -0.05 | - | 73.72 | 31.8 | 4.26 |
Investing Cash Flow | -92.09 | -83.91 | -59.48 | 13.38 | 90.92 |
Long-Term Debt Issued | 252.93 | 170.94 | 159.55 | 245.59 | 380.7 |
Total Debt Issued | 252.93 | 170.94 | 159.55 | 245.59 | 380.7 |
Long-Term Debt Repaid | -314.36 | -180.87 | -267.3 | -255.77 | -436.89 |
Total Debt Repaid | -314.36 | -180.87 | -267.3 | -255.77 | -436.89 |
Net Debt Issued (Repaid) | -61.44 | -9.93 | -107.74 | -10.18 | -56.19 |
Issuance of Common Stock | - | 15.94 | - | - | 13.72 |
Common Dividends Paid | -16.49 | -19.87 | -24.34 | -26.51 | -40.68 |
Other Financing Activities | - | -0.2 | 0.3 | - | -26.46 |
Financing Cash Flow | -77.93 | -14.06 | -131.79 | -36.69 | -109.61 |
Foreign Exchange Rate Adjustments | -0.02 | 0.05 | -0 | 0.13 | 0.11 |
Net Cash Flow | -48.79 | -26.47 | -120.57 | 6.14 | -7.25 |
Free Cash Flow | 29.12 | -21.04 | -66.87 | -29.57 | -208.64 |
Free Cash Flow Margin | 6.25% | -4.45% | -9.04% | -5.52% | -24.94% |
Free Cash Flow Per Share | 0.06 | -0.05 | -0.15 | -0.07 | -0.46 |
Cash Income Tax Paid | 40.37 | 64.58 | 36.1 | 29.57 | 62.33 |
Levered Free Cash Flow | 92.8 | 13.89 | -135.65 | -18.76 | -236.8 |
Unlevered Free Cash Flow | 92.8 | 27.06 | -119.84 | -1.64 | -225.09 |
Change in Working Capital | 189.33 | 136.57 | -68.04 | 83.11 | -48.21 |